1.83Open1.83Pre Close0 Volume240 Open Interest280.00Strike Price0.00Turnover39.09%IV11.39%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry1.83Extrinsic Value100Contract SizeAmericanOptions Type0.1328Delta0.0099Gamma180.72Leverage Ratio-0.1353Theta0.0155Rho24.01Eff Leverage0.1193Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet